PCM
ANIP icon

Penserra Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Penserra Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,598
Closed -$1.06M – 1057
2025
Q3 		$1.06M Buy
+11,598
New +$946K 0.01% 433
2021
Q4 		– Sell
-290
Closed -$9K – 1364
2021
Q3 		$9K Hold
290
– – ﹤0.01% 1365
2021
Q2 		$10K Buy
290
+10
+4% +$340 ﹤0.01% 1269
2021
Q1 		$10K Sell
280
-5
-2% -$157 ﹤0.01% 1033
2020
Q4 		$8K Buy
285
+181
+174% +$5.18K ﹤0.01% 948
2020
Q3 		$2K Buy
+104
New +$3.1K ﹤0.01% 902

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's ANIP Position: Q4 2025 in Review

Penserra Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 11,598 shares — an estimated $1.06M sold.

Penserra Capital Management first reported a position in ANIP in Q3 2020 and held it in 6 quarters. The position peaked at $1.06M in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Penserra Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Penserra Capital Management sold 11,598 ANI Pharmaceuticals shares in Q4 2025, an estimated $1.06M.
  • Penserra Capital Management first reported a position in ANI Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Penserra Capital Management's ANI Pharmaceuticals position peaked at $1.06M in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Penserra Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.